D
David Neal Franz
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 156
Citations - 11910
David Neal Franz is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Tuberous sclerosis & Everolimus. The author has an hindex of 49, co-authored 151 publications receiving 10457 citations. Previous affiliations of David Neal Franz include Boston Children's Hospital & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
John J. Bissler,Francis X. McCormack,Lisa R. Young,Jean M. Elwing,Gail Chuck,Jennifer Leonard,Vincent J. Schmithorst,Tal Laor,Alan S. Brody,Judy A. Bean,Shelia Salisbury,David Neal Franz +11 more
TL;DR: Angiomyolipomas regressed somewhat during sirolimus therapy but tended to increase in volume after the therapy was stopped, suggesting suppression of mTOR signaling might constitute an ameliorative treatment in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Journal ArticleDOI
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Darcy A. Krueger,Marguerite M. Caré,Katherine D. Holland,Karen Agricola,Cynthia Tudor,Prajakta Mangeshkar,Kimberly Wilson,Anna W. Byars,Tarek Sahmoud,David Neal Franz +9 more
TL;DR: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed.
Journal ArticleDOI
Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs
Sandra L. Dabora,Sergiusz Jozwiak,David Neal Franz,Penelope S. Roberts,Andres Nieto,Joon Chung,Yew-Sing Choy,Yew-Sing Choy,Mary Pat Reeve,Elizabeth A. Thiele,John C. Egelhoff,Jolanta Kasprzyk-Obara,Dorota Domańska-Pakieła,David J. Kwiatkowski +13 more
TL;DR: The reduced severity of disease in patients without defined mutations suggests that many of these patients are mosaic for a TSC2 mutation and/or have TSC because of mutations in an as-yet-unidentified locus with a relatively mild clinical phenotype.
Journal ArticleDOI
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz,Elena Belousova,Steven Sparagana,E. Martina Bebin,Michael Frost,Rachel Kuperman,Olaf Witt,Michael Kohrman,J. Robert Flamini,Joyce Y. Wu,Paolo Curatolo,Petrus J. de Vries,Vicky Whittemore,Elizabeth A. Thiele,James Ford,Gaurav D. Shah,Helene Cauwel,David Lebwohl,Tarek Sahmoud,Sergiusz Jozwiak +19 more
TL;DR: These results support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberousclerosis.
Journal ArticleDOI
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
David Neal Franz,Jennifer Leonard,Cynthia Tudor,Gail Chuck,Marguerite M. Caré,Gopalan Sethuraman,Argirios Dinopoulos,George Thomas,Kerry R. Crone +8 more
TL;DR: This work sought to see whether therapy with oral rapamycin could affect growth or induce regression in astrocytomas associated with TSC.